Informatie:
Fout:
ID
34167
Beschrijving
Cardiotoxicity of Adjuvant Trastuzumab; ODM derived from: https://clinicaltrials.gov/show/NCT00858039
Link
https://clinicaltrials.gov/show/NCT00858039
Trefwoorden
Versies (1)
- 14-01-19 14-01-19 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
14 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Breast Neoplasms NCT00858039
Eligibility Breast Neoplasms NCT00858039
- StudyEvent: Eligibility
Similar models
Eligibility Breast Neoplasms NCT00858039
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
female 18 years or older
boolean
ID.2
Item
histologically confirmed, completely excised invasive breast cancer with her-2 overexpression
boolean
ID.3
Item
primary surgery less than twelve weeks prior to registration
boolean
ID.4
Item
lvef>50% as assessed by transthoracic echocardiogram or gated heart pool scan
boolean
ID.5
Item
eastern cooperative oncology group performance status 0-2
boolean
ID.6
Item
adjuvant systemic treatment plan comprises at least three cycles of anthracycline chemotherapy and 52 weeks of trastuzumab
boolean
ID.7
Item
before patient registration, informed consent must be given according to local regulations.
boolean
ID.8
Item
pregnancy
boolean
ID.9
Item
distant metastases from breast cancer
boolean
ID.10
Item
any systemic chemotherapy prior to study entry
boolean